Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 Alone and in Combination With Palbociclib in Women With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT03455270 is registered in ClinicalTrials.gov with G1 Therapeutics, Inc. as lead sponsor.

NCT NCT03455270
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03455270 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 Alone and in Combination With Palbociclib in Women With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Lead sponsor
G1 Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
May 9, 2018
Completion date
September 29, 2022
Enrollment
107 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, breast cancer, breast cancer female, breast neoplasm, carcinoma, ductal, breast, metastatic breast cancer, stage iv breast cancer